IP Library Granted Patent US 7,465,448
Granted Patent B2
US 7,465,448 · App. 10/660,131 · Granted Dec 16, 2008

Chemokine receptor antagonists as therapeutic agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,465,448
App. No.
10/660,131
Granted
Dec 16, 2008
Kind
B2
Abstract

The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.

Claims (5)

1. A method to reduce recruitment of IDO+ dendritic cells that inhibit T-cell proliferation to at least one of a tumor or a tumor-draining lymph node in a subject comprising administering a composition comprising an antibody to CCR6 to the subject, wherein the IDO+ dendritic cells express CCR6 and elevated levels of indoleamine 2,3-dioxygenase (IDO), and tumor cells of the at least one of a tumor or a tumor draining lymph node express MIP-3a.

2. The method of claim 1 , wherein the subject is human.

3. The method of claim 1 , wherein the CCR6 antibody blocks the interaction between the CCR6 expressed by the IDO+ dendritic cells and the MIP-3α expressed by tumor cells of the at least one of a tumor or a tumor draining lymph node.

4. The method of claim 1 , further comprising the step of determining that IDO+ dendritic cells are recruited to the at least one of a tumor or a tumor-draining lymph node.

5. The method of claim 1 , wherein the MIP-3α mediates recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor draining lymph node.

Assignments (6)
CHANGE OF NAME Recorded Oct 30, 2013
From: GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC.
To: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
Reel/Frame 031515/0853 →
CHANGE OF NAME Recorded Oct 24, 2013
From: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
To: GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 031485/0631 →
CONFIRMATORY LICENSE Recorded Aug 2, 2010
From: MEDICAL COLLEGE OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024776/0151 →
CONFIRMATORY LICENSE Recorded Jul 19, 2010
From: MEDICAL COLLEGE OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024697/0659 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jul 22, 2008
From: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021273/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2004
From: MUNN, DAVID H.; MELLOR, ANDREW L.; PEIPER, STEPHEN C.
To: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
Reel/Frame 015299/0835 →